NASDAQ:APMD

Apnimed (APMD) Stock Price, News & Analysis

Apnimed logo
$17.25 -0.20 (-1.15%)
As of 04:00 PM Eastern

About Apnimed Stock (NASDAQ:APMD)

Advanced

Key Stats

Today's Range
$16.54
▼
$17.61
50-Day Range
$14.16
▼
$29.00
52-Week Range
$13.88
▼
$35.29
Volume
197,616 shs
Average Volume
448,263 shs
Market Capitalization
$718.13 million
P/E Ratio
6.56
Dividend Yield
N/A
Price Target
$50.33
Consensus Rating
Moderate Buy

Company Overview

Apnimed is a clinical-stage pharmaceutical company focused on developing medicines for sleep-related breathing disorders, particularly obstructive sleep apnea. The company aims to offer drug-based treatment options for people who may not use or benefit from existing device-based therapies.

Its lead candidate, AD109, is an investigational oral combination of atomoxetine and aroxybutynin (oxybutynin) designed to help maintain upper-airway muscle activity during sleep. Apnimed has evaluated AD109 in clinical trials for obstructive sleep apnea; it is not an approved treatment.

Apnimed is based in Cambridge, Massachusetts. Its research and development efforts are centered on advancing pharmaceutical treatments for sleep apnea and related conditions.

AI Generated. May Contain Errors.

Apnimed Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
79th Percentile Overall Score

APMD MarketRank™: 
3.94144144144 of 5 stars

Apnimed scored higher than 79% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Apnimed has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.

  • Upside Potential

    Apnimed has a consensus price target of $50.33, representing about 191.8% upside from its current price of $17.25.

  • Amount of Analyst Coverage

    Apnimed has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Apnimed's stock forecast and price target.
  • Earnings Growth

    Earnings for Apnimed are expected to decrease in the coming year, from ($0.24) to ($3.47) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Apnimed is 6.56, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.65.

  • Percentage of Shares Shorted

    3.81% of the float of Apnimed has been sold short.
  • Short Interest Ratio / Days to Cover

    Apnimed has a short interest ratio ("days to cover") of 4.54.
  • Change versus previous month

    Short interest in Apnimed has recently decreased by 12.03%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Apnimed does not currently pay a dividend.

  • Dividend Growth

    Apnimed does not have a long track record of dividend growth.

  • News Sentiment

    Apnimed has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Apnimed this week, compared to 2 articles on an average week.
  • Search Interest

    Only 1 people have searched for APMD on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    3 people have added Apnimed to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Apnimed insiders have not sold or bought any company stock.

  • Percentage Held by Institutions

    Apnimed has minimal institutional ownership at this time.

  • Read more about Apnimed's insider trading history.
Receive APMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Apnimed and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

APMD Stock News Headlines

Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.tc pixel
See More Headlines

APMD Stock Analysis - Frequently Asked Questions

Apnimed's stock was trading at $25.00 on July 31, 2026. Since then, APMD shares have decreased by 31.0% and is now trading at $17.25.

Apnimed, Inc. (NASDAQ:APMD) released its earnings results on Monday, November, 16th. The company reported ($1.05) earnings per share for the quarter. The firm had revenue of $2.48 million for the quarter.

Apnimed (APMD) raised $192 million in an initial public offering (IPO) on Friday, July 31st 2026. The company issued 12,000,000 shares at a price of $16.00 per share.

Apnimed's lock-up period expires on Wednesday, January 27th. Apnimed had issued 12,000,000 shares in its public offering on July 31st. The total size of the offering was $192,000,000 based on an initial share price of $16.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the end of the lock-up period.

Top institutional shareholders of Apnimed include Integral Health Asset Management LLC (0.54%) and Bellevue Group AG (0.01%).
View institutional ownership trends
.

Shares of APMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
11/16/2026
Today
11/19/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
N/A
Industry
N/A
Sub-Industry
N/A
Current Symbol
NASDAQ:APMD
CIK
1745648
Fax
N/A
Employees
81
Year Founded
N/A

Price Target and Rating

High Price Target
$60.00
Low Price Target
$41.00
Potential Upside/Downside
+191.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
6 Analysts

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
6.56
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.19
Quick Ratio
5.19

Sales & Book Value

Annual Sales
$115.12 million
Price / Sales
6.24
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
41,631,000
Free Float
N/A
Market Cap
$718.13 million
Optionable
Optionable
Beta
N/A
The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

This page (NASDAQ:APMD) was last updated on 11/19/2026 by MarketBeat.com Staff.
From Our Partners